John Neis is a Managing Director of Venture Investors LLC, early stage venture capital firm with offices in Madison, Wisconsin and Ann Arbor, Michigan. The firm’s venture capital funds are focused on opportunities emerging from leading research universities in the Midwest. John leads the firm and heads the firm’s Health Care practice. He currently serves on the Board of Directors of Virent, Inc., Deltanoid Pharmaceuticals, Inc., Novelos Therapeutics, Inc. (NVLT.OB), Inviragen, Inc. and Mithridion, Inc. He is a former member of the Board of Directors of several firms including TomoTherapy, Inc. (NASDAQ:TOMO – acquired by Accuray), Third Wave Technologies, Inc. (NASDAQ:TWTI – acquired by Hologic) and NimbleGen Systems, Inc. (acquired by Roche). He was appointed by the Governor to the Board of the Wisconsin Technology Council, the science and technology advisor to Wisconsin’s Governor and Legislature. He also serves on the Weinert Applied Ventures Program Advisory Board in the School of Business, Tandem Press Advisory Board in the School of Education at the University of Wisconsin–Madison. He was named to the 2008 and 2009 Midas Lists, Forbes annual list of the top 100 tech dealmakers in the world. He holds a B.S. in finance from the University of Utah, and received a M.S. in Marketing and Finance from the University of Wisconsin–Madison. He is a Chartered Financial Analyst.